Literature DB >> 26170991

In vitro and in vivo antitumor effects of 50 to 100-KDa components from B16 melanoma culture supernatant.

Ying-Song Qin1, X U Zhang2, Xiang-Yu Zhang3.   

Abstract

The development of immunological therapies for melanoma has been of considerable concern in recent years. Whole tumor cell lysates have been used to develop antitumor vaccines, but the effective components of the lysates have not been identified. In the present study, protein elements were purified from the B16 supernatant to analyze the in vitro chemotaxis towards mouse spleen lymphocytes using a Boyden chamber. Prior to establishing a B16 melanoma model, C57BL/6 mice were vaccinated with these proteins, and melanoma growth, tumor appearance time and behavioral changes were observed. Next, the cytotoxicity and subsets of the tumor infiltrating lymphocytes, and the histological characteristics of the melanoma were analyzed. The isolated purified fragments of B16 melanoma culture supernatant had strong antitumor effects. The possible antitumor mechanism was delineated, and was identified to possibly be through the activation of cluster of differentiation 8-positive T cells and the promotion of B16 cell differentiation. These methods will provide a novel insight into understanding antitumor immunological mechanisms and provide a potential avenue for immunotherapy.

Entities:  

Keywords:  chemotaxis; culture supernatant; immune killing; tumor infiltrating lymphocyte; vaccination

Year:  2015        PMID: 26170991      PMCID: PMC4487182          DOI: 10.3892/ol.2015.3239

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Authors:  Mikayel Mkrtichyan; Anahit Ghochikyan; Hayk Davtyan; Nina Movsesyan; Dmitry Loukinov; Victor Lobanenkov; David H Cribbs; Amanda K Laust; Edward L Nelson; Michael G Agadjanyan
Journal:  Cell Immunol       Date:  2011-05-12       Impact factor: 4.868

3.  Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.

Authors:  Martin K Hunn; Kathryn J Farrand; Kate W R Broadley; Robert Weinkove; Peter Ferguson; Rose J Miller; Cameron S Field; Troels Petersen; Melanie J McConnell; Ian F Hermans
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

Review 4.  Tumor-infiltrating T lymphocytes: friends or foes?

Authors:  Ping Yu; Yang-Xin Fu
Journal:  Lab Invest       Date:  2006-03       Impact factor: 5.662

5.  Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.

Authors:  Nai-peng Cui; Shao-jian Xie; Jin-sheng Han; Zhen-feng Ma; Bao-ping Chen; Jian-hui Cai
Journal:  Chin Med J (Engl)       Date:  2012-03       Impact factor: 2.628

6.  Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.

Authors:  Maja Bürdek; Stefani Spranger; Susanne Wilde; Bernhard Frankenberger; Dolores J Schendel; Christiane Geiger
Journal:  J Transl Med       Date:  2010-09-28       Impact factor: 5.531

7.  Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions.

Authors:  Chikage Obata; Manxin Zhang; Yoichi Moroi; Hajime Hisaeda; Keiji Tanaka; Shigeo Murata; Masutaka Furue; Kunisuke Himeno
Journal:  J Dermatol Sci       Date:  2004-05       Impact factor: 4.563

8.  Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line.

Authors:  Wing-Keung Liu; Joyce C K Ho; Florence W K Cheung; Bonnie P L Liu; Wen-Cai Ye; Chun-Tao Che
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

9.  Fusions between dendritic cells and whole tumor cells as anticancer vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

10.  Tumor-targeting vaccination instructs graft-vs.-tumor immune responses.

Authors:  Teresa Manzo; Rodrigo Hess Michelini; Tabea Sturmheit; Veronica Basso; Matteo Bellone; Anna Mondino
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.